ERBB2 and breast cancer: T-DXd has also been recently approved in Europe for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy [4], based on the results from the DESTINY-Breast04 trial.